fig6

Figure 6. Ivosidenib increases the sensitivity of ovarian cancer organoids to cisplatin. (A) Representative images of PDO1 from ovarian cancer patient treated with DMSO, 10 μM Ivosidenib, 20 μM Cisplatin, or their combination for 72 h. Scale bar: 50 μm. (B-D) The CellTiter-Glo Luminescence Assay of PDO1, PDO2, and PDO3. Data are represented as mean ± SD. ns, not significant, *P <0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using a one-way ANOVA followed by Tukey's post hoc test for multiple comparisons.